Clinical Trial Update: DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SGX942 (domino) for oral mucositis in head and neck cancer patients undergoing chemoradiation has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Mucositis
• Squamous Cell Carcinoma of the Oral Cavity and Oropharynx

Drugs mentioned

• SGX942 (SGX942)

Snippet

Sponsor: Soligenix | Conditions: Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis | Phase 3 | Status: COMPLETED | Results posted: 2022-08-29